ArticleVeterinary research communications2026
Fluralaner, an innovative ectoparasiticide for use in cattle: UFLC-MS/MS method development and validation for its pharmacokinetic characterization.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluralaner (FLR) is an isoxazoline ectoparasiticide of increasing interest for use in cattle due to growing resistance to conventional antiparasitic compounds. Reliable analytical methods are required to support its pharmacokinetic characterisation and future residue and formulation studies. This study aimed to develop and validate an Ultra-Fast Liquid Chromatography-Tandem Mass Spectrometry (UFLC-MS/MS) method for determining FLR in bovine plasma and to investigate its pharmacokinetic behaviour following intravenous administration. Plasma samples were processed by solid-phase extraction and analysed using UFLC–MS/MS under optimised chromatographic and mass spectrometric conditions. The method was validated according to regulatory guidelines, showing linear response within the working range (10–200 ng/mL), limits of detection and quantification of 5 and 10 ng/mL, recovery rates of 95.4–114.5%, negligible matrix effects, and a coefficient of variation ≤ 10% for accuracy and precision. Stability under frozen storage was confirmed. Method applicability was demonstrated in a pharmacokinetic study conducted in four calves following intravenous administration of FLR (2.5 mg/kg). Plasma concentrations remained quantifiable up to 28 days post-administration, with detectable trace levels (LOD ≤ C ≤ LOQ) persisting until day 42. FLR showed high initial plasma concentrations (C₀: 1162.9 ng/mL), prolonged systemic exposure (AUC: 4400.5 ± 819.6 ng·day/mL), extensive tissue distribution (Vss: 3.7 ± 0.8 L/kg), and a long terminal elimination half-life (t₁/₂β: 6.1 ± 0.5 days). Overall, these results confirm the suitability of the validated UFLC–MS/MS method for pharmacokinetic applications and provide the first intravenous pharmacokinetic characterisation of FLR in cattle, establishing a baseline for future studies exploring its behaviour following administration by other therapeutic routes.
Indexed as
Identifiers
41964807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.